When two COVID-19 treatments go head-to-head: what NHS data can teach us
During the COVID-19 pandemic, clinicians urgently needed treatments for patients sick enough to be admitted to hospital. Among the drugs repurposed for severe COVID-19 were two medicines originally developed for inflammatory diseases such as rheumatoid arthritis: tocilizumab and sarilumab
